China Biologics Market Size, Share, Growth and Industry Analysis 2032
The China Biologics Market is expanding rapidly as China strengthens its biotechnology ecosystem and healthcare infrastructure. According to Market Research Future, the market was valued at USD 46.22 billion in 2024 and is projected to reach USD 278.42 billion by 2035, registering a CAGR of 17.73% during the forecast period.
Increasing demand for advanced therapies is one of the major factors supporting market growth. The rising prevalence of chronic diseases, cancer, autoimmune disorders, and other complex conditions is encouraging healthcare providers and pharmaceutical companies to adopt biologic medicines. Personalized medicine is also becoming increasingly important as advances in genomic research and precision diagnostics support more targeted treatment approaches.
Monoclonal antibodies currently represent the dominant product segment, accounting for approximately 55% of the market. Cell and gene therapies are emerging rapidly because of advances in biotechnology and growing interest in precision medicine. Oncology is another major application area, representing approximately 48% of the market.
Government support, biotechnology investments, improved regulatory frameworks, and advances in biomanufacturing are creating favorable conditions for industry expansion. The growing adoption of biosimilars is also improving affordability and increasing access to biologic therapies.
With continued research, technological innovation, strategic collaborations, and expanding healthcare infrastructure, the China biologics industry is expected to remain an important growth market through 2035.